山东大学学报 (医学版) ›› 2023, Vol. 61 ›› Issue (7): 63-71.doi: 10.6040/j.issn.1671-7554.0.2023.0013
• 临床医学 • 上一篇
亓倩1,2*,郝田宇1*,徐嘉蔚1,王光海1,吴凤娟3,刘明涛4,姜鹏5,董亮1,李玉6
QI Qian1,2*, HAO Tianyu1*, XU Jiawei1, WANG Guanghai1, WU Fengjuan3, LIU Mingtao4, JIANG Peng5, DONG Liang1, LI Yu6
摘要: 目的 评估呼吸科医师对支气管扩张症诊治的认知现状,为推进支气管扩张症管理策略提供参考依据。 方法 2020年10月至2022年6月对山东地区143家医院的呼吸科医师围绕“支气管扩张症的诊治”进行问卷调查,比较各级医院及各级职称的呼吸科医师对支气管扩张症的病因鉴别、疾病严重性评估、诊断和治疗等各个方面的认知现状。 结果 共608名呼吸科医师完成问卷调查,其中24.7%的医师从未进行体液免疫检测,仅168名(27.6%)医师了解支气管扩张症严重程度评分。三级医院的医师对支气管扩张症病因鉴别以及铜绿假单胞菌清除治疗的认知水平高于二级医院的医师(OR=1.952,95%CI:1.253~3.041,P=0.003;OR=2.495,95%CI:1.543~4.035,P<0.001)。阅读支气管扩张症指南的医师对支气管扩张症病因鉴别以及疾病严重程度评估的认知水平高于未阅读指南的医师(OR=1.725,95%CI:1.027~2.897,P=0.039;OR=2.067,95%CI:1.361~3.138,P=0.001)。 结论 山东地区呼吸科医师(尤其二级医院医师)对支气管扩张症管理策略的认知水平仍需加强,需继续推广病因筛查及精简的疾病严重程度评估方法。
中图分类号:
[1] Sin S, Yun SY, Kim JM, et al. Mortality risk and causes of death in patients with non-cystic fibrosis bronchiectasis [J]. Respir Res, 2019, 20(1): 271. doi: 10.1186/s12931-019-1243-3. [2] Diel R, Ewig S, Blaas S, et al. Incidence of patients with non-cystic fibrosis bronchiectasis in Germany-A healthcare insurance claims data analysis [J]. Respir Med, 2019, 151: 121-127. doi: 10.1016/j.rmed.2019.04.007. [3] Choi H, Yang B, Nam H, et al. Population-based prevalence of bronchiectasis and associated comorbidities in South Korea [J]. Eur Respir J, 2019, 54(2): 1900194. doi: 10.1183/13993003.00194-2019. [4] 周玉民, 王辰, 姚婉贞, 等. 我国7省市城区40岁及以上居民支气管扩张症的患病情况及危险因素调查[J]. 中华内科杂志, 2013, 52(5): 379-382. ZHOU Yumin, WANG Chen, YAO Wanzhen, et al. The prevalence and risk factors of bronchiectasis of residents aged 40 years old and above in seven cities in China [J]. Chinese Journal of Internal Medicine, 2013, 52(5): 379-382. [5] Hill AT, Sullivan AL, Chalmers JD, et al. British Thoracic Society guideline for bronchiectasis in adults [J]. Thorax, 2019, 74(Suppl 1): 1-69. [6] Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis [J]. Eur Respir J, 2017, 50(3): 1700629. doi: 10.1183/13993003.00629-2017. [7] Chang AB, Fortescue R, Grimwood K, et al. European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis [J]. Eur Respir J, 2021, 58(2): 2002990. doi: 10.1183/13993003.02990-2020. [8] Martinez-Garcia MA, Maiz L, Olveira C, et al. Spanish guidelines on the evaluation and diagnosis of bronchiectasis in adults [J]. Arch Bronconeumol, 2018, 54(2): 79-87. [9] Martinez-Garcia MA, Maiz L, Olveira C, et al. Spanish guidelines on treatment of bronchiectasis in adults [J]. Arch Bronconeumol, 2018, 54(2): 88-98. [10] 成人支气管扩张症诊治专家共识编写组. 成人支气管扩张症诊治专家共识[J].中华结核和呼吸杂志, 2012, 35(7): 485-492. [11] 支气管扩张症专家共识撰写协作组, 中华医学会呼吸病学分会感染学组. 中国成人支气管扩张症诊断与治疗专家共识[J]. 中华结核和呼吸杂志, 2021, 44(4): 311-321. Bronchiectasis Expert Consensus Writing Group, Pulmonary Infection Assembly, Chinese Thoracic Society. Expert consensus on the diagnosis and treatment of adult bronchiectasis in China [J]. Chinese Journal of Tuberculosis and Respiratory Diseases, 2021, 44(4): 311-321. [12] Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index. An international derivation and validation study [J]. Am J Respir Crit Care Med, 2014, 189(5): 576-585. [13] Choate R, Aksamit TR, Mannino D, et al. Pseudomonas aeruginosa associated with severity of non-cystic fibrosis bronchiectasis measured by the modified bronchiectasis severity score(BSI)and the FACED: the US bronchiectasis and NTM Research Registry(BRR)study [J]. Respir Med, 2020, 177: 106285. doi: 10.1016/j.rmed.2020.106285. [14] Martinez-Garcia MA, Athanazio RA, Girón R, et al. Predicting high risk of exacerbations in bronchiectasis: the E-FACED score [J]. Int J Chron Obstruct Pulmon Dis, 2017, 12: 275-284. doi: 10.2147/COPD.S121943. [15] Shoemark A, Ozerovitch L, Wilson R. Aetiology in adult patients with bronchiectasis [J]. Respir Med, 2007, 101(6): 1163-1170. [16] McShane PJ, Naureckas ET, Strek ME. Bronchiectasis in a diverse US population: effects of ethnicity on etiology and sputum culture [J]. Chest, 2012, 142(1): 159-167. [17] Eastham KM, Fall AJ, Mitchell L, et al. The need to redefine non-cystic fibrosis bronchiectasis in childhood [J]. Thorax, 2004, 59(4): 324-327. [18] Qi Q, Wang W, Li T, et al. Aetiology and clinical characteristics of patients with bronchiectasis in a Chinese Han population: a prospective study [J]. Respirology, 2015, 20(6): 917-924. [19] Guan W, Gao Y, Xu G, et al. Aetiology of bronchiectasis in Guangzhou, southern China [J]. Respirology, 2015, 20(5): 739-748. [20] Gupta S, Pattanaik D, Krishnaswamy G. Common variable immune deficiency and associated complications [J]. Chest, 2019, 156(3): 579-593. [21] 王宁, 徐金富. 欧洲成人支气管扩张症管理指南带给我们的思考[J]. 中华结核和呼吸杂志, 2019, 42(2): 153-156. [22] 徐金富, 柴燕华. 支气管扩张症患者下呼吸道分离出铜绿假单胞菌的临床意义和对策[J]. 中华结核和呼吸杂志, 2019, 42(7): 506-509. XU Jinfu, CHAI Yanhua. Clinical implication and management of Pseudomonas aeruginosa colonization in patients with bronchiectasis [J]. Chinese Journal of Tuberculosis and Respiratory Diseases, 2019, 42(7): 506-509. [23] White L, Mirrani G, Grover M, et al. Outcomes of pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis [J]. Respir Med, 2012, 106(3): 356-360. [24] Durfey SL, Pipavath S, Li A, et al. Combining ivacaftor and intensive antibiotics achieves limited clearance of cystic fibrosis infections [J]. mBio, 2021, 12(6): e0314821. doi: 10.1128/mbio.03148-21. [25] Kaehne A, Milan SJ, Felix LM, et al. Head-to-head trials of antibiotics for bronchiectasis[J]. Cochrane Database Syst Rev, 2018, 9(9): CD012590. doi: 10.1002/14651858.CD012590.pub2. [26] Hernando R, Drobnic ME, Cruz MJ, et al. Budesonide efficacy and safety in patients with bronchiectasis not due to cystic fibrosis [J]. Int J Clin Pharm, 2012, 34(4): 644-650. [27] Martinez-Garcia MA, Soler-Cataluna JJ, Catalan-Serra P, et al. Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis [J]. Chest, 2012, 141(2): 461-468. [28] Goyal V, Chang AB. Combination inhaled corticosteroids and long-acting beta2-agonists for children and adults with bronchiectasis [J]. Cochrane Database Syst Rev, 2014, 2014(6): CD010327. doi: 10.1002/14651858.CD010327.pub2. [29] Kapur N, Petsky HL, Bell S, et al. Inhaled corticosteroids for bronchiectasis [J]. Cochrane Database Syst Rev, 2018, 5(5): CD000996. doi: 10.1002/14651858.CD000996.pub3. [30] Shoemark A, Shteinberg M, De Soyza A, et al. Characterisation of eosinophilic bronchiectasis: a European multicohort study [J]. Am J Respir Crit Care Med, 2022, 205(8): 894-902. [31] 王玲, 师一涵, 杨恒, 等. 支气管扩张症年度进展2021 [J]. 中华结核和呼吸杂志, 2022, 45(6): 592-597. WANG Ling, SHI Yihan, YANG Heng, et al. Annual review of bronchiectasis in 2021 [J]. Chinese Journal of Tuberculosis and Respiratory Diseases, 2022, 45(6): 592-597. |
[1] | 黄珊,娄能俊,韩晓琳,梁中昊,华梦羽,庄向华,陈诗鸿. 高糖环境下Lipin1对神经元代谢组学的影响[J]. 山东大学学报 (医学版), 2023, 61(2): 1-8. |
[2] | 宋洛卿,周国钰,叶翔,卢梅,赵新静. 脑淀粉样血管病相关炎症长期误诊1例报道并文献复习[J]. 山东大学学报 (医学版), 2022, 60(4): 119-122. |
[3] | 李献云,杨甫德. 自杀倾向的认知行为治疗[J]. 山东大学学报 (医学版), 2022, 60(4): 1-9. |
[4] | 赵慧文,许琳,单姗,赵秀兰. 牛磺酸对1-溴丙烷致大鼠认知功能障碍的保护作用[J]. 山东大学学报 (医学版), 2022, 60(2): 14-21. |
[5] | 于书卷,王美娟,陈丽,曹英娟,吕晓燕,刘雪燕,林鹏,颜景政. 老年2型糖尿病患者轻度认知功能障碍的影响因素[J]. 山东大学学报 (医学版), 2022, 60(11): 108-112. |
[6] | 王克芳,吴臣. 慢性病管理依从问题研究的困境及“破局”思路[J]. 山东大学学报 (医学版), 2021, 59(9): 124-129. |
[7] | 李宁,王翠兰,张玉荣. 帕金森病患者脑动脉多普勒测定指数及血清表皮生长因子与动脉硬化和认知障碍的关联分析[J]. 山东大学学报 (医学版), 2021, 59(3): 61-66. |
[8] | 刘新雨,王权,琚号杰,孙晓杰. 认知功能在老年人社会资本与身体功能健康间的中介作用[J]. 山东大学学报 (医学版), 2021, 59(11): 100-107. |
[9] | 孔文程,徐广润,贾俊丽,崔新宇. 脑腱黄瘤病1例并文献复习[J]. 山东大学学报 (医学版), 2021, 59(11): 72-75. |
[10] | 赵继宗. 神经外科学是脑科学研究的一支主力军[J]. 山东大学学报 (医学版), 2020, 1(8): 1-4. |
[11] | 王余余,高丽,陈少华. 94例2型糖尿病患者急性脑梗死后认知障碍与甲状腺功能的关联性[J]. 山东大学学报 (医学版), 2020, 58(5): 56-61. |
[12] | 高春媛,刘星亮,娄展,刘占矿,岳秉宏. 轻度脑白质疏松症患者认知能力与搏动指数的相关性[J]. 山东大学学报 (医学版), 2020, 58(4): 95-99. |
[13] | 张晓倩,孟祥水,任庆国,南晓敏,安盼盼,帅欣艳,夏晓娜,王璇. 磁共振波谱成像对检测非痴呆型血管性认知障碍的探讨[J]. 山东大学学报 (医学版), 2019, 57(4): 42-46. |
[14] | 宋立敏,鲁珊珊, 王大伟,吕鑫,高原,唐吉友. 慢性失眠患者睡眠结构与注意力、记忆的相关性[J]. 山东大学学报 (医学版), 2019, 57(4): 52-58. |
[15] | 薛付忠. 健康医疗大数据驱动的健康管理学理论方法体系[J]. 山东大学学报(医学版), 2017, 55(6): 1-29. |
|